Format

Send to

Choose Destination
See comment in PubMed Commons below
Arthritis Res Ther. 2015 Mar 19;17:66. doi: 10.1186/s13075-015-0554-0.

Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.

Author information

1
Mapi, De Molen 84, 3995, AX, Houten, The Netherlands. avanwalsem@mapigroup.com.
2
Novartis Pharma AG, Lichtstrasse 35, CH-4002, Basel, Switzerland. shaloo.pandhi@novartis.com.
3
Novartis Pharma AG, Lichtstrasse 35, CH-4002, Basel, Switzerland. richard.nixon@novartis.com.
4
Mapi, De Molen 84, 3995, AX, Houten, The Netherlands. pguyot@mapigroup.com.
5
Mapi, De Molen 84, 3995, AX, Houten, The Netherlands. akarabis@mapigroup.com.
6
University of Oxford, Old Road, Headington, OX3 7LE, Oxford, UK. andrew.moore@ndcn.ox.ac.uk.

Abstract

INTRODUCTION:

There is argument over the benefits and risks of drugs for treating chronic musculoskeletal pain. This study compared the efficacy, safety, and tolerability of diclofenac, ibuprofen, naproxen, celecoxib, and etoricoxib for patients with pain caused by osteoarthritis (OA) or rheumatoid arthritis (RA).

METHODS:

A systematic literature review used Medline and EMBASE to identify randomised controlled trials. Efficacy outcomes assessed included: pain relief measured by visual analogue scale (VAS); Western Ontario McMaster Universities Arthritis Index (WOMAC) VAS or WOMAC Likert scale; physical functioning measured by WOMAC VAS or Likert scale; and patient global assessment (PGA) of disease severity measured on VAS or 5-point Likert scale. Safety outcomes included: Antiplatelet Trialists' Collaboration (APTC), major cardiovascular (CV) and major upper gastrointestinal (GI) events, and withdrawals. Data for each outcome were synthesized by a Bayesian network meta-analysis (NMA). For efficacy assessments, labelled doses for OA treatment were used for the base case while labelled doses for RA treatment were also included in the sensitivity analysis. Pooled data across dose ranges were used for safety.

RESULTS:

Efficacy, safety, and tolerability data were found for 146,524 patients in 176 studies included in the NMA. Diclofenac (150 mg/day) was likely to be more effective in alleviating pain than celecoxib (200 mg/day), naproxen (1000 mg/day), and ibuprofen (2400 mg/day), and similar to etoricoxib (60 mg/day); a lower dose of diclofenac (100 mg/day) was comparable to all other treatments in alleviating pain. Improved physical function with diclofenac (100 and 150 mg/day) was mostly comparable to all other treatments. PGA with diclofenac (100 and 150 mg/day) was likely to be more effective or comparable to all other treatments. All active treatments were similar for APTC and major CV events. Major upper GI events with diclofenac were lower compared to naproxen and ibuprofen, comparable to celecoxib, and higher than etoricoxib. Risk of withdrawal with diclofenac was lower compared to ibuprofen, similar to celecoxib and naproxen, and higher than etoricoxib.

CONCLUSIONS:

The benefit-risk profile of diclofenac was comparable to other treatments used for pain relief in OA and RA; benefits and risks vary in individuals and need consideration when making treatment decisions.

PMID:
25879879
PMCID:
PMC4411793
DOI:
10.1186/s13075-015-0554-0
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center